Glaukos Co. (NYSE:GKOS) Holdings Raised by Corient Private Wealth LLC

Corient Private Wealth LLC grew its stake in shares of Glaukos Co. (NYSE:GKOS) by 1.1% in the 4th quarter, HoldingsChannel reports. The firm owned 30,241 shares of the medical instruments supplier’s stock after acquiring an additional 341 shares during the quarter. Corient Private Wealth LLC’s holdings in Glaukos were worth $4,534,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of GKOS. IFP Advisors Inc purchased a new stake in shares of Glaukos during the fourth quarter valued at $43,000. Asset Planning Inc purchased a new stake in shares of Glaukos during the fourth quarter valued at $90,000. Harvest Fund Management Co. Ltd lifted its holdings in shares of Glaukos by 2,263.2% during the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 860 shares during the last quarter. Picton Mahoney Asset Management purchased a new stake in shares of Glaukos during the fourth quarter valued at $125,000. Finally, SBI Securities Co. Ltd. acquired a new position in Glaukos during the fourth quarter valued at $153,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $102.02 on Friday. The business has a 50 day moving average price of $135.32 and a 200 day moving average price of $136.53. Glaukos Co. has a twelve month low of $87.31 and a twelve month high of $163.71. The company has a market cap of $5.77 billion, a price-to-earnings ratio of -35.55 and a beta of 0.99. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million. Research analysts predict that Glaukos Co. will post -1.08 earnings per share for the current year.

Insider Activity at Glaukos

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the sale, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

GKOS has been the topic of several recent analyst reports. Mizuho raised Glaukos from a “neutral” rating to an “outperform” rating and upped their price target for the company from $140.00 to $200.00 in a research report on Wednesday, February 19th. Morgan Stanley lowered Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a research report on Monday, December 2nd. Piper Sandler reissued an “overweight” rating and set a $180.00 price target (up from $140.00) on shares of Glaukos in a research report on Monday, January 27th. Truist Financial upped their price target on Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Finally, UBS Group initiated coverage on Glaukos in a research report on Friday, December 6th. They set a “buy” rating and a $182.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $163.25.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.